Ophthalmology biotech using a proprietary hydrogel implant to deliver drugs inside the eye long-acting.
Ophthalmology biotech using a proprietary hydrogel implant to deliver drugs inside the eye long-acting.
Dextenza, a steroid insert placed in the eyelid after cataract surgery, brings in the product revenue, but it is small beside the cost of late-stage trials for Axpaxli, so the company has depended on raising capital. Axpaxli, if approved for wet macular degeneration, would compete with repeated eye injections.
Moat: narrow (IP / patents, process know-how). Proprietary hydrogel depot technology for sustained intraocular drug release is patent-protected.
Headquarters: Bedford, Massachusetts, US · Founded: 2006 · Employees: 325
Size Ocular Therapeutix (OCUL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2064th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.94 on 18 Nov 2026.
Performance Over six months the shares fell 26.0%, against -17.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 9.7% over the last twelve months (peer median +9.2%); the operating margin is -680.9% (peer median 10.9%).
Valuation It trades at 17.0× enterprise value to sales against a peer median of 4.0× (4th most expensive of 16).
Short interest Short interest is 13.2% of the free float (30 Oct 2026).
Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $50.4M | $52.0M | $63.7M | $58.4M | $51.5M |
| Revenue growth | — | -18% | +9% | +13% | — |
| Gross profit | $42.8M | $45.4M | $58.1M | $53.2M | $47.0M |
| EBITDA | -$336M | -$266M | -$168M | -$79.4M | -$76.5M |
| Net income | -$327M | -$266M | -$194M | -$80.7M | -$71.0M |
| Free cash flow | -$267M | -$217M | -$136M | -$76.3M | -$63.3M |
| Capital expenditure | $13.9M | $12.0M | $1.29M | $6.09M | $3.71M |
| Total debt | $80.0M | $77.0M | $75.8M | $83.4M | $64.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ocular Therapeutix OCUL | $1.31B | -26% | -10% | -681% | 17.0× | n/a |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
| EyePoint EYPT | n/a | -98% | n/a | n/a | n/a | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OCUL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.7% | -4.1% | 5th lowest of 20 |
| 6-month return | -26.0% | -17.3% | 6th lowest of 20 |
| Distance from 52-week high | -63.9% | -37.5% | 2nd lowest of 20 |
| Revenue growth (TTM) | -9.7% | +9.2% | 3rd lowest of 16 |
| Operating margin | -680.9% | 10.9% | lowest of 16 |
| EV / Sales | 17.0× | 4.0× | 4th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |